Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1826 in advanced hepatocellular cancer
NCT06935175Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1826 in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Planned start May 2025; status: not yet recruiting.
02
Drugs
SHR-1826
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06935175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06935175.